Nektar Therapeutics (NASDAQ:NKTR)’s share price rose 7% during trading on Thursday . The company traded as high as $108.50 and last traded at $108.44. Approximately 2,086,830 shares were traded during mid-day trading, a decline of 25% from the average daily volume of 2,766,009 shares. The stock had previously closed at $101.30.
NKTR has been the topic of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $80.00 price objective (up previously from $50.00) on shares of Nektar Therapeutics in a report on Wednesday, January 10th. Mizuho boosted their price objective on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 14th. JPMorgan Chase & Co. reiterated a “buy” rating and issued a $44.00 price objective on shares of Nektar Therapeutics in a report on Monday, November 13th. Jefferies Group boosted their price objective on shares of Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Cowen reiterated a “buy” rating and issued a $101.00 price objective on shares of Nektar Therapeutics in a report on Friday, March 2nd. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $52.62.
The company has a market cap of $17,420.00, a PE ratio of -169.28 and a beta of 1.96. The company has a debt-to-equity ratio of 2.79, a current ratio of 5.82 and a quick ratio of 5.63.
Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.14. The company had revenue of $95.47 million during the quarter, compared to the consensus estimate of $36.96 million. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company’s revenue was up 154.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.28) EPS. research analysts predict that Nektar Therapeutics will post -1.33 EPS for the current year.
In other news, SVP Stephen K. Doberstein sold 2,426 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $82.94, for a total value of $201,212.44. Following the completion of the sale, the senior vice president now owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher A. Kuebler sold 40,000 shares of the business’s stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $97.60, for a total transaction of $3,904,000.00. Following the completion of the sale, the director now directly owns 43,100 shares of the company’s stock, valued at approximately $4,206,560. The disclosure for this sale can be found here. Insiders sold a total of 482,925 shares of company stock valued at $40,642,596 in the last three months. Insiders own 6.10% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in NKTR. California Public Employees Retirement System grew its position in shares of Nektar Therapeutics by 2.3% during the 3rd quarter. California Public Employees Retirement System now owns 195,200 shares of the biopharmaceutical company’s stock valued at $4,685,000 after buying an additional 4,300 shares during the last quarter. Advisor Partners LLC bought a new stake in shares of Nektar Therapeutics during the 4th quarter valued at about $393,000. Systematic Financial Management LP grew its position in shares of Nektar Therapeutics by 1.8% during the 3rd quarter. Systematic Financial Management LP now owns 745,979 shares of the biopharmaceutical company’s stock valued at $17,903,000 after buying an additional 12,949 shares during the last quarter. Aperio Group LLC grew its position in shares of Nektar Therapeutics by 14.6% during the 4th quarter. Aperio Group LLC now owns 49,830 shares of the biopharmaceutical company’s stock valued at $2,976,000 after buying an additional 6,345 shares during the last quarter. Finally, Alps Advisors Inc. grew its position in shares of Nektar Therapeutics by 9.9% during the 3rd quarter. Alps Advisors Inc. now owns 153,958 shares of the biopharmaceutical company’s stock valued at $3,695,000 after buying an additional 13,915 shares during the last quarter. 94.96% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Nektar Therapeutics (NKTR) Stock Price Up 7%” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/10/nektar-therapeutics-nktr-stock-price-up-7.html.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.